Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Oncol. 1988 Jun;15(3 Suppl 4):71-3.

Mitomycin C in advanced breast cancer: an update.

Author information

  • Loma Linda University School of Medicine, California.

Abstract

Mitomycin C has a documented response rate of 20% to 30% when used as treatment in advanced breast cancer. Because of its delayed and cumulative hematologic toxicity, there has been a reluctance to use this agent. However, by lowering the drug dosage, the hematologic, pulmonary, and renal toxicities have been reduced. The reduced dosage does not appear to have compromised the treatment results.

PMID:
3134697
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk